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A proportion of people living with common variable
immunodeﬁciency disorders develop granulomatous-
lymphocytic interstitial lung disease (GLILD). We aimed to
develop a consensus statement on the deﬁnition, diagnosis, and
management of GLILD. All UK specialist centers were contacted
and relevant physicians were invited to take part in a 3-round
online Delphi process. Responses were graded as Strongly Agree,
Tend to Agree, Neither Agree nor Disagree, Tend to Disagree,
and Strongly Disagree, scored D1, D0.5, 0, L0.5, and L1,
respectively. Agreement was deﬁned as greater than or equal to
80% consensus. Scores are reported as mean – SD. There was
100% agreement (score, 0.92 – 0.19) for the following
deﬁnition: “GLILD is a distinct clinico-radio-pathological ILD
occurring in patients with [common variable immunodeﬁciency
disorders], associated with a lymphocytic inﬁltrate and/or
granuloma in the lung, and in whom other conditions have been
considered and where possible excluded.” There was consensus
that the workup of suspected GLILD requires chest computed
tomography (CT) (0.98 – 0.01), lung function tests (eg, gas
transfer, 0.94 – 0.17), bronchoscopy to exclude infection (0.63 –
0.50), and lung biopsy (0.58 – 0.40). There was no consensus on
whether expectant management following optimization of
immunoglobulin therapy was acceptable: 67% agreed, 25%
disagreed, score 0.38 – 0.59; 90% agreed that when treatment
was required, ﬁrst-line treatment should be with corticosteroids
alone (score, 0.55 – 0.51). ! 2017 The Authors. Published by
Elsevier Inc. on behalf of the American Academy of Allergy,
Asthma & Immunology. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/). (J Allergy Clin Immunol Pract 2017;-:---)
Key words: Common variable immunodeﬁciency; Lung Disease;
Interstitial; Complications
INTRODUCTION
Although common variable immunodeﬁciency disorders
(CVID) are primarily characterized by hypogammaglobulinemia
and increased risk of infection, noninfectious autoinﬂammatory,
autoimmune, and lymphoproliferative complications are also com-
mon.1 Notably, 8% to 22% of people living with CVID develop
an interstitial lung disease termed “granulomatous-lymphocytic
interstitial lung disease” (GLILD), which is associated with reduced
survival.2 This important complication of GLILD has been little
studied. Investigators have used different deﬁnitions, including
diffuse radiological abnormalities and/or biopsy evidence of granu-
lomatous inﬂammation, with lymphoproliferative changes
including histologic patterns of lymphoid interstitial pneumonia
(LIP), follicular bronchitis, and/or diffuse reactive lymphoid hy-
perplasia.3 ImpairedT-cell function leading to dysfunctional antigen
handling has been proposed as a possible mechanism,4 perhaps in
association with reduced switched memory B cells,5,6 and/or aber-
rant responses to viral infection.7Management is primarily based on
small case series,8-10 and there have been no controlled trials. This is
unsatisfactory both for people livingwithGLILD and for health care
professionals.
In 2015, a UK consortium from London (University College
London, Barts and Imperial), Cambridge, and Oxford estab-
lished a network of clinicians with an interest in GLILD, to
develop patient literature, and to produce a consensus document
on the deﬁnition, diagnosis, and management of GLILD in
adults. This was funded by the British Lung Foundation and
achieved in collaboration with the United Kingdom Primary
Immunodeﬁciency Network, using Delphi methodology.
The Delphi technique, ﬁrst used in the 1950s to assess the
impact of new military technology, has been widely used in
health care to develop consensus documents. Key characteristics
include anonymity of the participants, structured ﬂow of infor-
mation, and faeedback to individuals of group data from previous
rounds to inform subsequent responses.11
We report the results of a Delphi consensus process providing a
statement on the deﬁnition, diagnosis, and management of
GLILD in adults. This has not been previously performed and
represents the largest report to date of collective clinical experience
in GLILD. We provide a deﬁnition for future studies, illuminate
current practice, and help to deﬁne future research priorities.
METHODS
A structured questionnaire containing a proposed deﬁnition of
GLILD, and statements on diagnosis and management, was devel-
oped by the Steering Committee (Delphi Round 1).
For Delphi Round 2, all UK centers providing specialist
immunology services were contacted via the UK Primary
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Immunodeﬁciency Network and asked to nominate interested
consultant immunologists, chest physicians, radiologists, and
pathologists to take part. The role of consultant in the United
Kingdom signiﬁes a senior physician who is on a national register in
their respective specialty. Participants were therefore self-selected as
those with an interest in GLILD. The number of participants was
not restricted. These participants completed the questionnaire via a
Web link (SurveyMonkey). Participants did not have to answer all
the questions; thus, for example, a radiologist might only answer
sections on radiology. We report the number of respondents for each
question.
Responses were graded, unless stated otherwise, as Strongly Agree,
Tend to Agree, Neither Agree nor Disagree, Tend to Disagree, and
Strongly Disagree, scored þ1, þ0.5, 0, "0.5, and "1, respectively.
This is illustrated as Figure 1. A priori, agreement was deﬁned as
80% or greater consensus to Agree (Strongly or Tend to), or
Disagree (Strongly or Tend to). Scores are reported as the mean and
SD, on a scale of þ1 to "1, with more extreme scores and lower SD
indicating stronger consensus.
The Steering Committee reviewed the Round 2 summary
responses and where further clariﬁcation was required, the question
was adapted and sent back to participants with feedback from Round
2 as the third and ﬁnal round. The process was designed to complete
after the third round, reporting consensus or otherwise.
RESULTS
The Steering Committee that developed the questionnaire
consisted of a facilitator (N.V., a senior trainee in Immunology)
and 12 consultants: 5 immunologists, 4 chest physicians, 2
radiologists, and 1 pathologist.
Thirty-three consultants completed the second round Delphi,
consisting of 17 immunologists, 8 chest physicians, 4 radiolo-
gists, and 4 pathologists. This included representation from 13
centers in total, including 6 of the 10 Royal College of Physicians
“Quality in Primary Immunodeﬁciency Services (QPIDS)”-
accredited centers. In total, the participating centers estimated
that they currently cared for 112 patients with GLILD (median,
4; interquartile range, 5-9; minimum, 2; maximum, 24). Thirty-
one consultants completed the third and ﬁnal round Delphi.
Definition of GLILD
After revision for the ﬁnal round Delphi, 24 of 29 strongly
agreed and 5 of 29 tended to agree with the following deﬁnition
of GLILD, which we therefore present as a British Lung Foun-
dation/United Kingdom Primary Immunodeﬁciency Network
consensus deﬁnition (100% agree; score, 0.91 # 0.19): “GLILD
is a distinct clinico-radio-pathological ILD occurring in patients
with CVID, associated with a lymphocytic inﬁltrate and/or
granuloma in the lung, and in whom other conditions have been
considered and where possible excluded.”
Importantly, there was also consensus that GLILD is usually
seen in the context of multisystem granulomatous/inﬂammatory
involvement that might include, for example, splenomegaly,
lymphadenopathy, and/or liver disease, even if these manifesta-
tions are not symptomatic (93% agree; score, 0.66 # 0.31).
Diagnosis of GLILD
There was no consensus that patients with GLILD must be
symptomatic: 63% disagreed with this statement,
score "0.27 # 0.64. This was true for both major symptoms of
GLILD: change in (or new) breathlessness (score, "0.22 # 0.61)
and change in (or new) cough (score, "0.29 # 0.61); 96%
agreed that the diagnosis of GLILD required a high index of
suspicion, supporting a strategy of screening for respiratory
complications of CVID.
A total of 88% agreed that the diagnosis of GLILD required
discovery of new abnormalities on chest imaging (score,
0.65 # 0.56) and therefore all respondents felt that a computed
tomography (CT) scan was essential in the diagnostic workup
(score, 0.98 # 0.01). The results of consensus opinion on other
aspects of the diagnostic workup are reported in Table I.
The other tests considered essential in diagnostic workup were
full lung function (spirometry 96% agreed, 0.88 # 0.27; lung
volumes 91% agreed, 0.76 # 0.40; and gas transfer 100%
agreed, 0.94 # 0.17), ﬂexible bronchoscopy to exclude infection
(83% agreed, 0.63 # 0.50), and surgical lung biopsy (83%
agreed, 0.58 # 0.46); 96% preferred video-assisted thoracic
surgical biopsy to open thoracotomy (score, 0.85 # 0.28). There
were no radiological ﬁndings considered sufﬁciently diagnostic to
avoid the need for biopsy (score, "0.05 # 0.61). There was no
consensus that there had to be new change on lung function tests
to make the diagnosis (54% agreed; 33% disagreed; score, 0.04
# 0.67) and therefore the value of lung function testing is pri-
marily in assessing progression and treatment response rather
than establishing the diagnosis (as described further below).
There was no consensus on the need to perform other imaging
tests (including chest x-ray and magnetic resonance imaging chest),
functional tests (including oxygen saturation, 6-minute or shuttle-
walk, or cardiopulmonary exercise testing), echocardiography, or
blood tests (including inﬂammatory markers, b2-microglobulin,
serum angiotensin converting enzyme (ACE), or serum IgM).
Despite GLILD usually being associated with multisystem involve-
ment, there was no consensus for preference to biopsy another site in
the presence of such manifestations even if that was more practical
than surgical lungbiopsy (score, 0.27# 0.59). This likely reﬂects the
differential diagnosis in the lung discussed further below.
There was consensus that, where available, a diagnosis of
GLILD should prompt a search for speciﬁc underlying genetic
mutations, for example, LRBA/cytotoxic T-lymphocyte-associ-
ated protein 4 (CTLA-4) (81% agree; score, 0.57 # 0.36).
Radiology. Regarding the CT protocol, there was consensus
that this should be thin slice (<2 mm, 80% agree; score,
0.73 # 0.47) and contiguous (85% agree; score, 0.77 # 0.38).
There was no consensus about the administration of intravenous
contrast (62% agree, 8% disagree; score, 0.40 # 0.53).
FIGURE 1. Anchor statements and scoring.
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Bronchoscopy. With regard to samples obtained at ﬂexible
bronchoscopy, the tests considered essential are reported in
Table II. There was consensus to perform microscopy and
bacterial culture (96% agreement; score, 0.93 # 0.23),
Mycobacterial culture (96% agreement; score, 0.93 # 0.23), and
fungal culture (91% agreement; score, 0.80 # 0.33). There was
no consensus for other tests at bronchoscopy including trans-
bronchial biopsy, PCR for Mycobacteria, atypical pathogens, or
viruses, routine tests for Pneumocystis jirovecii, or analysis of
bronchoalveolar lavage ﬂuid for cell differential or lymphocyte
phenotyping.
Histopathology. There was 80% or more consensus
(n ¼ 20) that biopsy specimens should be immuno-stained for
CD3, CD4, CD8, and CD20, for the presence of
bacteria including Mycobacteria and fungi, and for clonality to
exclude lymphoma. Two respondents additionally
mentioned staining for viral markers including cytomegalo-
virus and EBV.
Differential diagnosis of GLILD
Respondents were asked to rate a list of radiological features as
“necessary to make the diagnosis of GLILD,” “typical of the
diagnosis of GLILD,” or “not typical of the diagnosis of
GLILD.” No features were consistently rated as necessary to
make the diagnosis. More than 80% of (22 of 25) respondents
rated the presence of solid nodules (nodule deﬁned as <3 cm),
semisolid nodules, pure ground-glass opacities, enlarged thoracic
(hilar and/or mediastinal) lymph nodes, and splenomegaly as
necessary or typical. More than 80% of respondents rated the
presence of cysts and bronchiectasis as not typical. There was no
consensus for reticulation, traction bronchiectasis, honey-
combing, masses (deﬁned as >3 cm), consolidation, or upper
abdominal adenopathy. When nodules were present, there was
no consensus about their distribution.
Results of the consensus on radiological differential diagnosis
are presented in Table III. There was consensus that this includes
infection, organizing pneumonia, lymphoid interstitial pneu-
monia, sarcoidosis, and lymphoma.
Respondents were also asked to rate a list of histopathological
features as “necessary to make the diagnosis of GLILD,” “typical
of the diagnosis of GLILD,” or “not typical of the diagnosis of
GLILD.” No features were consistently rated as necessary to
make the diagnosis. More than 80% of the respondents rated the
presence of granulomatous inﬂammation, peribronchiolar
lymphoid proliferation, interstitial lymphoid proliferation, and
CD4-cell predominance as typical. There was consensus that
eosinophils were not typical. There was no consensus for the
presence of organizing pneumonia, interstitial ﬁbrosis, or paucity
of B cells. Ninety-two percent agreed that the biopsy features are
TABLE I. Consensus on diagnostic workup of GLILD
Criteria
No. of
respondents
%
Agree
%
Disagree
Mean – SD
score*
“The following tests are essential in the workup of suspected GLILD”:
Consensus
CT Thorax 24 100 0 0.98 # 0.01
Spirometry 24 96 0 0.88 # 0.27
Lung volumes 23 91 4 0.76 # 0.40
Gas transfer 24 100 0 0.94 # 0.17
Flexible bronchoscopy
to exclude infection
23 83 4 0.63 # 0.50
Surgical lung biopsy 24 83 8 0.58 # 0.46
No consensus
Chest radiograph 23 65 9 0.48 # 0.57
MRI Chest 21 0 48 "0.40 # 0.46
Peripheral oxygen
saturation
23 74 13 0.52 # 0.65
6-minute or
Shuttle-Walk Test
24 58 17 0.31 # 0.57
Cardiopulmonary
Exercise Test
23 0 57 "0.39 # 0.40
Echocardiogram 24 33 29 0.06 # 0.60
Serum CRP 23 52 26 0.15 # 0.65
Serum
b2-microglobulin
24 29 38 "0.06 # 0.58
Serum ACE 24 50 25 0.25 # 0.68
Serum IgM 24 29 25 0.04 # 0.55
Percentage CD21low
B cells
24 33 25 0.02 # 0.40
Transbronchial biopsy 23 61 17 0.39 # 0.62
Bronchoalveolar lavage
cell differential
24 63 4 0.44 # 0.52
Bronchoalveolar lavage
immunophenotyping
23 30 17 0.00 # 0.48
ACE, Angiotensin converting enzyme; CRP, C-reactive protein; MRI, magnetic
resonance imaging.
*See text. Scale of "1 (strongly disagree) to þ1 (strongly agree), with more extreme
scores and smaller SD indicating greater consensus. Consensus deﬁned as %80%
agreement/disagreement.
TABLE II. Consensus on diagnostic testing of bronchoalveolar
lavage fluid obtained at flexible bronchoscopy for the investigation
of suspected GLILD
Criteria
No. of
respondents
%
Agree
%
Disagree
Mean – SD
score*
The following tests are essential in analysis of bronchoalveolar lavage
from suspected GLILD:
Consensus
BAL Microscopy and
culture
23 96 0 0.93 # 0.23
BAL Mycobacterial
culture
23 96 0 0.93 # 0.23
BAL Fungal culture 23 91 0 0.80 # 0.33
No consensus
BAL PCR for
Mycobacteria
23 61 9 0.46 # 0.58
BAL PCR for atypical
bacteria
23 70 9 0.50 # 0.50
BAL PCR for respiratory
viruses
23 74 4 0.61 # 0.48
BAL PCR for
Pneumocystis jirovecii
22 64 14 0.36 # 0.56
BAL Silver stain or
immunoﬂuorescence for
P jirovecii
21 48 10 0.31 # 0.49
BAL, Bronchoalveolar lavage.
*See text. Scale of "1 (strongly disagree) to þ1 (strongly agree), with more extreme
scores and smaller SD indicating greater consensus. Consensus deﬁned as %80%
agreement/disagreement.
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sufﬁciently typical to make a conﬁdent diagnosis in a person
known to have primary immunodeﬁciency.
Results of the consensus on histopathological differential
diagnosis are also presented in Table III. There was consensus
that this includes infection, organizing pneumonia, lymphoid
interstitial pneumonia due to other causes/associations, and
sarcoidosis.
Management of GLILD
There was strong support for decision making on manage-
ment being led by a multidisciplinary team including immu-
nologists, chest physicians, radiologists, and pathologists
(n ¼ 26, 100% agree; score, 0.90 # 0.20), for patients to be
managed in a multidisciplinary clinic comprising immunologists
and chest physicians (n ¼ 25, 96% agree; score, 0.90 # 0.25),
and for patients to have access to a nurse specialist (n ¼ 25, 84%
agree; score, 0.70 # 0.43) and psychological support (n ¼ 24,
96% agree; score, 0.79 # 0.29) as necessary.
Ninety-one percent (n ¼ 22; score, 0.68 # 0.33) agreed that
immunoglobulin therapy should be optimized to standard con-
centrations before initiation of speciﬁc therapy for GLILD, but
there was no consensus about targeting a higher trough level
(n ¼ 22, 64% agreed, 9% disagreed; score, 0.39 # 0.46).
There was no consensus about the routine use of antimicrobial
prophylaxis in patients with GLILD (n ¼ 21, 48% agreed, 19%
disagreed; score, 0.21 # 0.56). Where prophylactic antibiotics
were given, the most commonly used agents were azithromycin
and, particularly if there was a risk of Pneumocystis, cotrimox-
azole. There was no consensus that macrolides should be the
preferred agent because of potential anti-inﬂammatory activity.
There was no consensus about whether expectant manage-
ment (monitoring without additional therapy) following opti-
mization of immunoglobulin therapy was an acceptable strategy
(n ¼ 24, 67% agreed, 25% disagreed; score, 0.38 # 0.59). We
went on to explore, having made a diagnosis, which features of
GLILD were associated with a decision to commence additional
therapy, examining the presence or absence of symptoms, normal
versus abnormal and stable versus deteriorating lung function.
There was consensus to start treatment when patients were
symptomatic with abnormal and deteriorating lung function
(n ¼ 17, complete agreement), asymptomatic with abnormal and
deteriorating lung function (n ¼ 17, 100% agree; score, 0.79 #
0.25), and symptomatic with normal but deteriorating lung
function (n ¼ 16, 81% agree; score, 0.63 # 0.53). There was
consensus not to treat a patient who was asymptomatic with
normal and stable lung function (n ¼ 17, 94% agree;
score, "0.79 # 0.40). There was no consensus to treat or not for
the remaining 4 options.
Ninety percent agreed that when speciﬁc treatment was
required, ﬁrst-line treatment for GLILD should be with corti-
costeroids alone (n ¼ 21; score, 0.55 # 0.51). Of these 21
respondents, all but 1 preferred oral prednisone (1 preferred
intravenous methylprednisone). Of the 20 using oral prednisone,
the minimum dose used was 10 to 20 mg/d, and the maximum 1
to 2 mg/kg/d. For a 70-kg subject, the median (interquartile
range [IQR]) dose was 40 (30-70) mg/d. For respondents using
prednisone with a second agent, the 2 most commonly used
second agents were azathioprine (6 respondents) and mycophe-
nolate (4 respondents).
The consensus results regarding second-line drug therapy are
reported in Table IV. There was 80% or greater consensus for
the following 3 drugs as second-line agents, with or without
steroids, in decreasing order of support: azathioprine (n ¼ 21,
100% agreed; score, 0.71 # 0.25), rituximab (n ¼ 21, 90%
agreed; score, 0.67 # 0.40), and mycophenolate (n ¼ 21, 81%
agreed; score, 0.62 # 0.44). There was no consensus support for
abatacept (though potential use in patients with speciﬁc genetic
mutations was noted), anti-TNF agents, ciclosporin, hydroxyx-
chloroquine, methotrexate, sirolimus, or tacrolimus. There was
no consensus that biopsy at a single time point could be used to
guide future second-line therapy decisions: 43% agreed with the
statement that second-line therapy could be guided by lung
biopsy results and 24% disagreed with this (n ¼ 21). The
second-line agents that had been used in clinical practice, in
alphabetical order, were as follows: abatacept, adalimumab,
azathioprine, ciclosporin, hydroxychloroquine, inﬂiximab,
methotrexate, mycophenolate, and rituximab. Of the 22 partic-
ipants responding to the question “Would you consider bone-
marrow transplantation for GLILD?” 7 (32%) said yes, 7 said
no, and 8 were unsure.
Regarding opportunistic infections in the context of immu-
nosuppression for GLILD, 55% of respondents had seen
TABLE III. Differential diagnosis of GLILD
Criteria
No. of
respondents
%
Agree
%
Disagree
Mean – SD
score*
“The differential diagnosis of GLILD on radiology includes”:
Consensus
Infection 25 96 4 0.72 # 0.36
Organizing pneumonia 26 92 4 0.65 # 0.37
Lymphoid interstitial
pneumonia
26 81 12 0.52 # 0.54
Sarcoidosis 26 88 12 0.62 # 0.48
Lymphoma 26 96 0 0.69 # 0.29
No consensus
Nonspeciﬁc interstitial
pneumonia
24 63 17 0.31 # 0.55
Vasculitis 25 40 32 0.12 # 0.55
Invasive mucinous
adenocarcinoma
25 32 32 0.04 # 0.54
Pulmonary metastases 25 28 64 "0.16 # 0.55
“The differential diagnosis of GLILD on histopathology includes”:
Consensus
Infection 26 94 6 0.81 # 0.39
Organizing pneumonia 20 95 5 0.63 # 0.43
Lymphoid interstitial
pneumonia
20 80 5 0.70 # 0.47
Sarcoidosis 22 95 5 0.75 # 0.37
No consensus
Nonspeciﬁc interstitial
pneumonia
19 63 0 0.47 # 0.42
Usual interstitial
pneumonia
19 42 37 0.11 # 0.70
Follicular bronchitis 18 72 6 0.53 # 0.47
Hypersensitivity
pneumonia
20 70 15 0.38 # 0.56
*See text. Scale of "1 (strongly disagree) to þ1 (strongly agree), with more extreme
scores and smaller SD indicating greater consensus. Consensus deﬁned as %80%
agreement/disagreement.
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opportunistic infections including Pneumocystis, nontuberculous
Mycobacteria, cytomegalovirus, varicella zoster virus, and 1 case
of possible progressive multifocal leucoencephalopathy. Further
research is required here because these data are not incidence
rates.
There was consensus that treatment response (or progression)
could be assessed using change in symptoms (n ¼ 22, 91%
agreed; score, 0.64 # 0.38), change in lung function (n ¼ 22,
91% agreed; score, 0.75 # 0.40), and/or change in CT
appearance (n ¼ 22, 91% agreed; score, 0.77 # 0.40). The
single preferred test in 82% of 17 respondents was change in gas
transfer (DLCO and/or KCO); 63% of 19 respondents considered
a change in gas transfer of 10% to 20% to be signiﬁcant and
21% considered a change of 20% to 30% to be signiﬁcant. After
initiation of therapy, response was ﬁrst assessed a median (IQR)
of 3 (1.5-3) months later in 22 respondents; 9% of 22 partici-
pants would not repeat a CT, but in those who would the me-
dian (IQR) time to repeat was 5.5 (5.5-7.5) months.
There was no consensus about preferred maintenance therapy,
or indeed the need for maintenance thereapy, in clinically stable
disease. In 24 respondents, 46% would prefer a second-line
(noncorticosteroid) agent alone, 21% preferred a second-line
agent with a minimum continuing dose of corticosteroid, 13%
preferred corticosteroid alone, and 13% preferred to withdraw all
therapy and monitor.
In clinically stable disease, 55% of 22 respondents monitored
patients every 3 to 4 months, and 32% every 5 to 6 months;
55% of 22 respondents would consider a repeat lung biopsy in
the event of relapse.
DISCUSSION
We present the ﬁrst consensus statement on the deﬁnition,
diagnosis, and management of adult GLILD. This is not an
evidence-based treatment guideline, but it does permit individual
centers to compare their management against consensus. We
hope that the statements made below will be supported or
challenged by future research in this neglected condition. The
consensus is derived from 33 consultants working across 13
centers currently providing care to more than 100 patients with
GLILD, with contributions from immunology, respiratory
medicine, radiology, and pathology. It is therefore the largest
record of shared experience in managing GLILD reported to
date.
We propose that GLILD should be deﬁned as “a distinct
clinico-radio-pathological ILD occurring in patients with CVID,
associated with a lymphocytic inﬁltrate and/or granuloma in the
lung, and in whom other conditions have been considered and
where possible excluded.” There was consensus that GLILD is
usually seen in the context of multisystem granulomatous and/or
inﬂammatory disease.6 Only by agreeing a deﬁnition can the
ﬁeld move forward with rational experimental studies. Opera-
tionally, this implies that a conﬁrmed diagnosis of GLILD
requires both pertinent CT and histopathological abnormalities.
The diagnosis may be suspected, but not conﬁrmed, when the
CT changes are considered typical but no biopsy has been
performed.
Patients with GLILD may or may not be symptomatic. Only
abnormalities on chest CT scan were felt essential for the diag-
nosis, with chest x-ray insufﬁciently sensitive. Our results sup-
port the need to screen patients with CVID for lung
complications. The workup of suspected GLILD requires
contiguous thin-slice CT chest, full lung function tests (for
subsequent monitoring), ﬂexible bronchoscopy to exclude
infection, and surgical lung biopsy (video-assisted thoracic sur-
gical biopsy) to conﬁrm the diagnosis and exclude differential
diagnoses. There was no consensus around the use of bron-
choalveolar lavage lymphocyte phenotyping, reﬂecting ongoing
controversy in the literature,12,13 nor around the use of trans-
bronchial biopsy for which yield has been reported to be vari-
able14 or endoscopic bronchial ultrasound for lymph node
sampling. Further studies are required to establish the feasibility
of less invasive diagnostic strategies.
The radiological and histopathological differential diagnosis
includes infection, organizing pneumonia, LIP due to other
causes/associations, and sarcoidosis. Lymphoma is an additional
radiological differential. These results are consistent with previ-
ous reports of the radiological features observed in GLILD,15 and
a recent report describing the heterogeneity of histopathological
ﬁndings in GLILD.16 However, there was consensus that biopsy
features were sufﬁciently typical to make a conﬁdent diagnosis in
a person known to have primary immunodeﬁciency. We deﬁned
consensus that lung biopsy specimens should be stained for
CD3, CD4, CD8, and CD20, for the presence of bacteria
including Mycobacteria and for fungi, and for clonality to exclude
lymphoma. The differential diagnosis of LIP and sarcoid
emphasizes the importance of assessing serum immunoglobulins
in patients presenting with these conditions, to exclude primary
immunodeﬁciency. In contrast to GLILD, sarcoid is typically
associated with hypergammaglobulinemia, hilar adenopathy, and
speciﬁc (upper zone predominant) distribution of nodules within
the lung. Further work is required to conﬁrm whether differences
in bronchoalveolar lavage lymphocyte subsets are able to differ-
entiate sarcoid from GLILD.12,13 The diagnostic workup of
granulomatous lung disease outside the context of known CVID
would include a full occupational and exposure history, imaging,
and autoimmune screen.
Immunoglobulin replacement should be optimized to stan-
dard guidelines before the initiation of therapy for GLILD. A
major current limitation is the absence of information on the
TABLE IV. Consensus on second-line drug therapy in GLILD
Criteria
No. of
respondents
%
Agree
%
Disagree
Mean – SD
score*
Which of the following drugs would you consider as second-line therapy
in GLILD?
Consensus
Azathioprine 21 100 0 0.71 # 0.25
Rituximab 21 90 5 0.67 # 0.40
Mycophenolate 21 81 5 0.62 # 0.44
No consensus
Abatacept 18 33 28 0.03 # 0.50
Anti-TNF agents 17 29 47 "0.12 # 0.57
Ciclosporin 16 25 25 0.00 # 0.48
Hydroxyxchloroquine 19 42 32 0.07 # 0.56
Methotrexate 17 35 29 0.03 # 0.51
Sirolimus 18 28 28 0.03 # 0.53
Tacrolimus 18 22 33 "0.08 # 0.43
*See text. Scale of "1 (strongly disagree) to þ1 (strongly agree), with more extreme
scores and smaller SD indicating greater consensus. Consensus deﬁned as %80%
agreement/disagreement.
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natural history of GLILD, but it has been reported that the
disease may progress despite optimal immunoglobulin replace-
ment,17 which provides a rationale for active therapy. Ongoing
observational studies such as Study of Interstitial Lung Disease in
Primary Antibody Deﬁciency (STILPAD) will inform further on
this. We were not able to reach consensus on whether initial
expectant management was an acceptable treatment option,
which therefore remains an open research question of particular
relevance for asymptomatic patients. There was consensus to
treat patients irrespective of symptoms in the presence of
abnormal and deteriorating lung function (as described further
below, and of the order of a 20% reduction in gas transfer), and
also to commence treatment in those who were symptomatic
with normal but deteriorating lung function. Further work is
required on biomarkers of disease progression, for example, IgM
and/or thrombocytopaenia.18 We recognize that in current
clinical practice, and the absence of screening for GLILD in
CVID, many patients may have been managed “expectantly”
because their lung disease has not (yet) been recognized.
There was consensus that when speciﬁc treatment for GLILD
was recommended, initial treatment should be with oral corti-
costeroids alone, despite a restricted evidence basis for such
practice. Steroids have been used in GLILD for many years.9,14
The median (IQR) dose of prednisone equivalent deemed
appropriate for a 70-kg subject was 40 (30-70) mg/d. Preferred
second-line agents, alone or in combination with corticosteroids,
were azathioprine, rituximab, and mycophenolate. Published case
series are available to support the use of combination azathioprine
and rituximab8 and mycophenolate.19 There was no consensus
for other therapeutic approaches, including bone-marrow trans-
plantation, and interventions for which case reports or case series
do exist including ciclosporin,20 anti-TNF therapy,21,22 and
abatacept (in the context of LRBA/CTLA-4 deﬁciency10).
However, no prospective randomized trials have been undertaken
to date, and the largest case series of second-line therapy describes
only 7 patients.8 Our results suggest that many other therapies
had been tried, without published evidence of success or other-
wise. It is important that as a community we report the results of
trials of novel agents, whether or not they are associated with
therapeutic success. Immunosuppression appears to be associated
with an increased risk of opportunistic as well as conventional
infections in this already immunodeﬁcient cohort but there was
no consensus on the routine use of antimicrobial prophylaxis.
There was also no consensus on the approach to management of
disease that is clinically stable, with some clinicians preferring to
continue treatment and others to withdraw, with continued
treatment consisting of corticosteroids and/or second-line agents.
We recognize that treatment needs to be individualized, including
taking account of comorbidities, and that treatment of other
manifestations of immune-mediated and inﬂammatory compli-
cations of CVID may complicate the treatment of GLILD.
Treatment response or progression should be assessed using
change in symptoms, lung function, and imaging. There are no
currently accepted scores to measure symptoms (if present) in
GLILD, although validated scores exist for both breathlessness
(such as the Medical Research Council scale) and cough (such as
the Leicester Cough Questionnaire). We suggest the need for a
validated patient-reported outcome measure in GLILD.
Although there was most support for imaging as the optimal
modality to detect treatment response or progression, a reluc-
tance to perform repeat CT scanning meant that the preferred
test to assess progression and/or response to therapy was gas
transfer. A change in gas transfer of the order of 20% was
generally considered signiﬁcant, assessed not more than 3
months after starting therapy. It is important to note that a
“normal” lung function measurement does not exclude signiﬁ-
cant deterioration if a patient previously had supranormal
physiology. What little data have been published would suggest
that vital capacity in GLILD remains stable over time.6 CT, if
repeated, was generally performed after 4 to 6 months of therapy.
It was noted that chest x-ray may be used to monitor disease, if
changes are initially visible. Monitoring in stable disease was
typically every 3 to 6 months.
Reﬂecting the complexity of management decisions, and the
uncertainty inherent in treatment and monitoring, there was
strong support for management decisions being made in a
multidisciplinary meeting and clinic, with access to specialist
nursing and psychological support as necessary. Uncertainty in
management also mandates the need for further research. This
Delphi process has been necessary because of the current absence
of robust evidence on which to base clinical decisions in GLILD.
We included an additional question on research priorities in our
survey. The 2 most frequent responses were a trial of expectant
versus immediate management and, for immediate management,
a randomized trial of corticosteroid versus combination therapy,
or a second-line agent alone, most frequently rituximab.
There are strengths and weaknesses of the Delphi method. Key
strengths include participant anonymity, and the opportunity to
revise opinions in the light of group results. Delphi is well suited
to the development of consensus documents.11 Potential disad-
vantages include low response rates, the time taken to complete
the questionnaires (typically 20 minutes for Round 2 in this case),
and the risk that the way feedback is presented can lead to
convergence. Our participants were a large group of self-selected
experts involved in the management of GLILD, including
consultant immunologists, chest physicians, radiologists, and pa-
thologists. All UK centers managing GLILD were invited to take
part. However, individual experience remains limited, even in
larger centers, and the process reports an average of such limited
experience with the potential for convergence of opinion. It must
also be recognized that the deﬁnition of consensus used, although
deﬁned a priori, is arbitrary,23 and this is why we have elected to
present the actual scores with SD in this report. Our deﬁnition of
consensus at 80% or greater is above, and therefore more robust
than the 75% median reported in a systematic review.23
GLILD is not new, with the ﬁrst report of LIP in the context
of hypogammaglobulinemia dating back to 1973.24 However,
although previously neglected, there is now increasing interest.
We recognize it is likely that ongoing genetic studies will dissect
the heterogeneity of CVID, and may provide the basis for a
future “precision medicine” approach to treat the complications
of CVID, including interstitial lung disease. Already this is
reaching the clinic; for example, GLILD in the context of
CTLA4 deﬁciency25,26 being treated with abatacept.10 The
future may therefore see a move away from the term GLILD, and
it is already recognized that a subset of patients with CVID are
more likely to experience lung complications: those with late-
onset combined immunodeﬁciency.27 However, the time frame
and feasibility of novel approaches remain undeﬁned, and there is
a current clinical imperative to establish the optimal treatment
for GLILD for the beneﬁt of our patients. As noted above,
important observational cohort studies in GLILD, notably
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STILPAD, are currently in progress and these will also inform
future treatment and management strategies. Finally, it is
possible that a deeper understanding of the pathogenesis of
autoimmune/autoinﬂammatory pathology in GLILD may
inform on the pathogenic mechanisms of other interstitial lung
diseases. Meanwhile, we present this consensus statement to the
community to promote debate. Most importantly, we aim to
facilitate and support further research. Only by doing this can we
move from this initial iteration of a consensus document to
evidence-based treatment guidelines for people living with this
neglected and challenging condition.
CONCLUSIONS
We present a consensus statement on the deﬁnition, diag-
nostic criteria, treatment, and monitoring of GLILD in CVID,
which can serve as a rational basis for experimental studies. This
is the largest collection of shared clinical experience in GLILD
ever recorded.
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